title: FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine.
authors.forename: Bob
authors.initials: B
authors.lastname: Roehr
mesh_terms: D006801:Humans; D040541:Marketing; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D055553:Prescription Drugs / Q000592:standards*; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D055553:Prescription Drugs